NICE reconsiders lung cancer drug

Responding to the decision by NICE, Cancerbackup and the Roy Castle Lung Cancer Foundation commented: “Today’s decision by NICE is encouraging because Tarceva provides another treatment option for people with lung cancer. It can give some patients extra time, which can be extremely valuable to them and their families.

“Until the NICE guidance is final, clinicians should continue to prescribe this treatment, as clearly stated by the reissued Health Service Circular. We hope that this treatment can now be swiftly approved and Tarceva made available to all those who could benefit from it.”